Millhouse
VC Fund
London, United Kingdom
Millhouse is a VC fund in London focused on Health Care and Software. Millhouse, Inc. PLC is a listed international diversified funds management business with its securities quoted on Deutsche Börse. Its business is to acquire existing businesses in funds management, investment management, and asset management across asset sectors. These acquisitions are conducted at historically low prices and capitalise on the considerable sunk costs invested by previous owners. The company has a standard acquisition model based on warranted ebitda with the consideration payable over three years as a mix of equity and cash. Each acquisition is ebitda positive and cash generating. Business operations exist in Australia, Singapore, Germany and other countries as the acquisitions program rolls out.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Millhouse invests in
Stages Millhouse invests in
Countries Millhouse invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $364k–$2.3M
- Series B
- $25M–$40M
- Venture - Series Unknown
- $1.5M–$21M
Investment Focus
Industry
- Health Care 7 (32%)
- Software 5 (23%)
- Biotechnology 4 (18%)
- Artificial Intelligence 4 (18%)
- Video 3 (14%)
Stage
- Seed 5 (23%)
- Venture - Series Unknown 5 (23%)
- Series B 4 (18%)
- Series A 3 (14%)
- Series C 3 (14%)
Country
- Israel 10 (45%)
- United States 7 (32%)
- United Kingdom 2 (9%)
- Russian Federation 2 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Roman Abramovich
CEO
|
CEO | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BrainQ develops a platform for precision neurology therapies to treat the impaired brain using a BCI-based approach. The company was founded in 2016 and is headquartered in Jerusalem, Yerushalayim, Israel. | $40M / Series B / Aug 16, 2021 | ||
| Ivi is a Russia-based video-on-demand platform that brings the traditional television experience online with a free video player that is secure, scalable, portable (accessible by any internet connected computer), and flexible for both broadcasters and viewers.Ivi creates opportunities for desktop and independent content producers to create livestreaming channels. ivi also provides mainstream broadcasters with new audiences and revenue opportunities. | $250M / Series D / May 26, 2021 | ||
| TARIS Biomedical a specialty pharmaceutical company with deep domain expertise in therapeutics and drug-delivery, is focused on local minimally-invasive drug-device convergence products. The TARIS core technology and development efforts are being applied to disease areas with high unmet medical need in which current therapies or systemic treatmentshave failed. | $25M / Series B / Dec 21, 2017 | ||
| OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma andhematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017. | $6M / Venture - Series Unknown / Dec 11, 2017 | ||
| StoreDot develops battery technology that supports extreme-fast charging for electric vehicles and related uses. The company focuses on silicon-dominant lithium-ion cells designed to deliver a significant driving range with only a few minutes of charging. StoreDot provides sample cells to automotive manufacturers and collaborates with industrypartners to explore the integration of its technology into future vehicle platforms. The company also advances research aimed at reducing charging times further while maintaining performance characteristics. | $60M / Series C / Aug 09, 2017 | ||
| Cleanly creates an alternative to their clients typical laundry and dry cleaning experience. | $5M / Series A / Apr 11, 2017 | ||
| At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $20M / Series C / Aug 18, 2016 | ||
| DreaMed Diabetes is a medical device, SaaS company providing personalized diabetes treatment optimization solutions. The company was established in 2014, commercializing the first artificial pancreas technology which was published in the NEJM. Eversince, DreaMed Diabetes has been vigorously working on decision support tools in the diabetesmanagement space and became the first and only company in the world to receive FDA clearance for a decision support system using data from CGM/SMBG and insulin pumps. We offer a clinically proven decision support system for insulin titration in type 1 diabetes patients. Our Advisor Pro software was created by diabetes professionals and is based on real-world experience, turbo-charged by artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. By frequent titration changes and online monitoring, we allow patients better treatment thus by lowering their A1C levels and risk for complications. Using the Advisor Pro physicians and nurses can provide true patient-centered care and everyone can receive the same top-level of treatment – wherever they are and whoever their caregiver is. | $3.3M / Venture - Series Unknown / Jul 25, 2016 | ||
| TransMedics provides technology and clinical service solutions, service for heart and lung transplant volume, clinical outcomes, and reduce learning curves. | $51.2M / Series F / May 26, 2016 | ||
| Via is a re-engineering public transit company that develops and provides on-demand public mobility solutions for commuters. The company transforms public transit from a regulated system of rigid routes and schedules to a fully dynamic, on-demand network. Via's mobile app connects passengers who are headed the same way, allowing riders toseamlessly share a premium vehicle. The platform operates in the United States and in Europe through its joint venture with Mercedes-Benz Vans, ViaVan. Via's technology is deployed worldwide through partner projects with public transportation agencies, private transit operators, taxi fleets, private companies, and universities, integrating with public transit infrastructure to power cutting-edge on-demand mobility.Via's software offers an end-to-end solution for planning, optimizing, and operating efficient and equitable transit systems, thereby unlocking opportunity for all and constructing resilient cities for the future. | $100M / Series C / May 05, 2016 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Millhouse invest in?
Millhouse invests primarily in Health Care, Software and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 22 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Millhouse invest in?
Millhouse typically joins rounds of $364k–$2.3M at Seed, $25M–$40M at Series B and $1.5M–$21M at Venture - Series Unknown. These are whole funding-round sizes, not Millhouse's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Millhouse took part in.
How do I contact Millhouse?
Public channels for Millhouse include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Millhouse?
The team at Millhouse includes Roman Abramovich (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
